Rivercyte
Rivercyte produces technology for the analysis of physical phenotypes of cells, including their deformability. Their core technology, deformability cytometry, uses a microfluidic chip and high-speed microscopy to analyze thousands of single cells per second, extracting parameters like stiffness, size, and shape. This label-free, functional method complements traditional flow cytometry by providing insights into cell mechanics, which are promising biomarkers for disease diagnosis and prognosis. Rivercyte aims to democratize this technology by making it easy-to-use and affordable. Their products include the Naiad device and CytoPlot software for cell analysis, along with consumables like microfluidic chips and measurement buffers. The company was founded in 2022 as a spin-off from the Max Planck Institute for the Science of Light.
Rivercyte
Rivercyte produces technology for the analysis of physical phenotypes of cells, including their deformability. Their core technology, deformability cytometry, uses a microfluidic chip and high-speed microscopy to analyze thousands of single cells per second, extracting parameters like stiffness, size, and shape. This label-free, functional method complements traditional flow cytometry by providing insights into cell mechanics, which are promising biomarkers for disease diagnosis and prognosis. Rivercyte aims to democratize this technology by making it easy-to-use and affordable. Their products include the Naiad device and CytoPlot software for cell analysis, along with consumables like microfluidic chips and measurement buffers. The company was founded in 2022 as a spin-off from the Max Planck Institute for the Science of Light.